Share on StockTwits
 

Quest Diagnostics (NYSE:DGX) Director Gail R. Wilensky sold 30,000 shares of Quest Diagnostics stock on the open market in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $52.93, for a total value of $1,587,900.00. Following the completion of the transaction, the director now directly owns 15,927 shares in the company, valued at approximately $843,016. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Quest Diagnostics (NYSE:DGX) opened at 52.77 on Thursday. Quest Diagnostics has a 1-year low of $50.46 and a 1-year high of $64.10. The stock has a 50-day moving average of $52.99 and a 200-day moving average of $58.04. The company has a market cap of $7.599 billion and a P/E ratio of 9.55.

Quest Diagnostics (NYSE:DGX) last released its earnings data on Thursday, January 30th. The company reported $0.97 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.93 by $0.04. The company had revenue of $1.76 billion for the quarter, compared to the consensus estimate of $1.74 billion. Analysts expect that Quest Diagnostics will post $4.03 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which is scheduled for Wednesday, April 23rd. Shareholders of record on Tuesday, April 8th will be given a dividend of $0.33 per share. This represents a $1.32 dividend on an annualized basis and a yield of 2.50%. The ex-dividend date of this dividend is Friday, April 4th. This is a positive change from Quest Diagnostics’s previous quarterly dividend of $0.30.

DGX has been the subject of a number of recent research reports. Analysts at Zacks upgraded shares of Quest Diagnostics from an “underperform” rating to a “neutral” rating in a research note on Friday, February 7th. They now have a $54.00 price target on the stock. Separately, analysts at SunTrust cut their price target on shares of Quest Diagnostics from $66.00 to $60.00 in a research note on Friday, January 31st. Finally, analysts at UBS AG cut their EPS estimates on shares of Quest Diagnostics in a research note on Friday. They now have a “neutral” rating and a $56.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $59.11.

Quest Diagnostics Incorporated (NYSE:DGX), is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.